Latest Market Research Report 2025

  The global antibody-drug conjugates (ADCs) market was valued at approximately USD 11.29 billion in 2023, with projections indicating a compound annual growth rate (CAGR) of 9.2% from 2024 to 2030. This growth is largely driven by a robust research and development (R&D) pipeline within the sector, which is enabling the continuous development of new and innovative ADCs. Additionally, the rising prevalence of cancer worldwide, coupled with an increasing demand for targeted therapies that offer high efficacy with minimal toxicity, is expected to fuel the market’s expansion. Several key ADCs currently dominate the market, including Kadcyla (Genentech/Roche), Adcetris (Seattle Genetics), Enhertu (AstraZeneca/Daiichi Sankyo), Besponsa (Pfizer), Mylotarg (Pfizer), and Polivy (Genentech/Roche). ADCs are a distinct class of therapeutic agents designed to deliver cytotoxic drugs directly to cancer cells. This is achieved by chemically linking a potent cytotoxic drug to an antibody, whic...

    The global antibody drug conjugates market was valued at USD 11.29 billion in 2023. It is expected to grow at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2030. This growth is driven by a strong R&D pipeline. There is also a rising incidence of cancer. The demand for low-toxicity and effective drugs supports market expansion. Key antibody drug conjugates (ADCs) currently available include Kadcyla, Adcetris, Enhertu, Besponsa, Mylotarg, and Polivy. ADCs are a novel class of drugs. They consist of an antibody linked to a cytotoxic drug via a chemical linker. Conventional chemotherapy targets fast-growing tumor cells. However, it can also harm healthy cells. ADCs aim to enhance treatment efficacy while reducing systemic toxicity. In developed economies, reimbursement policies significantly influence this market. ADCs are more expensive to produce than conventional treatments. This results in higher overall treatment costs. Such costs can challenge reimburseme...

  The global antibody drug conjugates (ADCs) market was estimated to be valued at USD 11.29 billion in 2023, with projections indicating a compound annual growth rate (CAGR) of 9.2% from 2024 to 2030. This anticipated growth can be largely attributed to a robust research and development pipeline, alongside the rising incidence of cancer and a growing demand for therapies that offer both low toxicity and high efficacy. Currently, several key ADCs are available in the market, including Kadcyla (Genentech/Roche), Adcetris (Seattle Genetics), Enhertu (AstraZeneca/Daiichi Sankyo), Besponsa (Pfizer), Mylotarg (Pfizer), and Polivy (Genentech/Roche). These drugs represent a novel class of therapeutics that combine an antibody with a cytotoxic drug through a chemical linker, enhancing targeted delivery to cancer cells. Gather more insights about the market drivers, restrains and growth of the  Antibody Drug Conjugates Market In contrast to conventional chemotherapy, which aims to elimi...

  Antibody Drug Conjugates Industry Overview The global  antibody drug conjugates market  size is expected to reach over USD 22.87 billion by 2030, registering a CAGR of 16.4% during the forecast period, according to a new report by Grand View Research Inc. The presence of strong pipeline products and strategic initiatives undertaken by the key players are expected to drive the market growth during the forecast period.   Antibody Drug conjugates Market Segmentation Grand View Research has segmented the global antibody-drug conjugates market based on the application, technology, and region:   Based on the Application Insights, the market is segmented into Blood Cancer, Breast Cancer, Urothelial Cancer & Bladder Cancer, and Other Cancer. Breast cancer accounted for the largest revenue share in 2021 owing to the relatively high prevalence of the disease worldwide. According to WHO, there were around 2.26 million new breast cancer cases diagnosed worldw...